Mathew Martoma is an American former hedge fund trader. As a portfolio manager at S.A.C. Capital Advisors, he was accused of generating possibly the largest single insider trading transaction profit in history at a value of $276 million . On November 20, 2014, he began serving a nine-year prison sentence. Contents. [hide].
Nov 20, 2012 ... Elan and Wyeth to present the final clinical trial results at a July 29, 2008 medical conference, which was to coincide with the after-market hours public announcement of the trial results by the two companies (the "July 29 Announcement"). 3. Martoma met Gilman through paid consultations that took place ...
Nov 20, 2012 ... The SEC alleges that Mathew Martoma illegally obtained confidential details about the clinical trial from Dr. Sidney Gilman, who served as chairman of the safety monitoring committee overseeing the trial. Dr. Gilman was selected by Elan Corporation and Wyeth to present the final drug trial results to the ...
Sep 22, 2011 ... Before: DAUGHTREY, GILMAN, and SUTTON, Circuit Judges. 1 ... Smith, et al. v. Wyeth, Inc., et al. Page 3. 1. Although Smith and Wilson claim to have consumed only generic metoclopramide, plaintiff. Morris does assert that he consumed some Reglan manufactured by Wyeth (but not Schwarz), a fact that.
Oct 13, 2014 ... By the time Gilman made his presentation, however, S.A.C. Capital no longer owned any stock in Elan or Wyeth. In the eight days preceding the conference, Cohen had liquidated his seven-hundred-million-dollar position in the two companies, and had then proceeded to “short” the stocks—to bet against ...
Aug 29, 2017 ... Predictably, Elan's and Wyeth's share prices increased following this announcement. A few weeks before the conference, Dr.Gilman learned that the trial results were actually worse than expected, and he immediately informed Martoma about the bad news, providing him with extensive data about the ...
Feb 6, 2014 ... NEW YORK (Reuters) - Mathew Martoma, a former portfolio manager at billionaire Steven A. Cohen's SAC Capital Advisors hedge fund, was found guilty on Thursday of engaging in what prosecutors called the most lucrative insider trading scheme in U.S. history.
On November 20, 2012, the SEC brought suit against CR Intrinsic Investors, LLC (“CR Intrinsic”) and Matthew Martoma and Dr. Sidney Gilman. ... losses in July 2008 by trading ahead of a negative public announcement involving the clinical trial results for an Alzheimer's drug being jointly developed by Elan and Wyeth.
Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear ...